GlassScriptPhysician profile
Thomas J Imperato
NPI 1902871684
$1,968.19
in general payments reported to CMS, 2019-2025
19 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $160 · 2021: $211 · 2022: $584 · 2023: $196 · 2024: $347 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $601.21 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $330.50 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $311.37 | 2019-2024 | Entyvio |
| Braintree Laboratories, INC. | $116.84 | 2022-2024 | Sutab |
| Ardelyx, INC. | $110.35 | 2022-2025 | Ibsrela |
| Abbvie INC. | $101.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $80.13 | 2022-2024 | Dificid |
| Qol Medical, LLC | $56.23 | 2019-2022 | |
| Madrigal Pharmaceuticals | $37.55 | 2024 | Resmetirom |
| Pfizer INC. | $30.29 | 2024-2025 | |
| Redhill Biopharma INC. | $27.42 | 2022 | |
| Intercept Pharmaceuticals, INC. | $25.86 | 2020 | |
| Aimmune Therapeutics, INC. | $23.29 | 2025 | Vowst |
| Ipsen Biopharmaceuticals, INC | $23.24 | 2025 | Iqirvo |
| Janssen Biotech, INC. | $19.72 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $18.91 | 2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $18.75 | 2019 | |
| Boston Scientific Corporation | $18.62 | 2024 | |
| Celltrion USA INC. | $16.50 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Imperato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.